News for Lexaria Bioscience Corp. (LEXXW)

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side

Lexaria Bioscience's DehydraTECH technology could address the GLP-1 industry's major challenge of gastrointestinal side effects. GLP-1 market projected

Lexaria Bioscience, known by its ticker LEXX, has strengthened its global patent repertoire, now totaling 50 patents worldwide, with the addition of two new int

New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscienc

Lexaria Bioscience (LEXX) achieves milestone with 50 patents granted globally. New Australian patent for epilepsy treatment extends protection until 204

KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery p

Lexaria Bioscience Corp. (LEXX) recently provided updates regarding its ongoing collaboration with a pharmaceutical partner. Initially announced on September 3,

Lexaria Bioscience Corp. (LEXX) completes initial pre-clinical pharmacokinetic animal studies under Material Transfer Agreement. Confidential results pe

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d

Lexaria Bioscience (NASDAQ: LEXX) successfully closes a $2 million registered direct offering. The offering was priced at $1.00 per share for 2,000,000

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 1% on Friday. The Dow traded down 0.17% to 40,024.00 while the NASDAQ...

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Friday. Following the market opening Friday, the Dow traded down 0...

Lexaria Bioscience Corp. (LEXX) has announced a $2 million registered direct offering of common stock at $1.00 per share. The offering is expected to cl

Florida-based Odyssey Marine Exploration, Inc. (OMEX) is up over 59 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELO

Lexaria Bioscience (LEXX) has provided a strategic update on its advancements in glucagon-like peptide-1 (GLP-1) technology, which potentially holds significant

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Cor

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-week